Press

Seelos Therapeutics Announces Year-End 2021 Business and Clinical Update

Mar 7 • 5 min read

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced its year-end 2021 business and clinical update. “In the second half of 2021, we continued to accomplish several significant milestones and continued to execute in the face of one of the…

Magellan Rx Management Releases Clinical Insights on the Use of Psychedelics in Treating Mental Health Conditions

Mar 4 • 3 min read

Magellan Rx Management, the full-service pharmacy benefits management division of Magellan Health, Inc. today released its Clinical Insights publication titled Therapeutic Psychedelics: an Emerging Frontier in Mental Health. The paper explores the role of psychedelics in treating mental health conditions, the current regulatory and legislative landscape, and Magellan Rx Management’s four-pillar evaluation on this emerging therapeutic frontier. Although psychedelics…

Love Pharma Updates Microdoz Proposed Acquisition with Global Leader in Psychedelic Research

Mar 4 • 4 min read

LOVE Pharma Co. (CSE: LUV | FSE: G1Q0), the Company is pleased to announce updated details on the proposed Microdoz Therapy acquisition (originally announced in a press release on November 23, 2021), whereby Microdoz has engaged exclusively with researchers at Johns Hopkins University, the top psychedelic center in the World, located in the eastern United States,…

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care

Mar 3 • 3 min read

Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP), a global leader in the development and delivery of psychedelic-assisted psychotherapy, today announced a strategic partnership with Cerebral, the fastest growing online mental health platform. The companies are launching a partnership where Cerebral clinicians can refer qualified clients to Field Trip Health’s ketamine assisted therapy, while Field Trip…

Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights

Mar 2 • 3 min read

Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2), a leading mental health company specialized in psychedelic medicine, reported its financial results for the three and six months ended December 31, 2021. All results are reported under International Financial Reporting Standards and in Canadian dollars, unless otherwise specified. “We’re pleased to report record high…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441